JNJ
JOHNSON & JOHNSON
Key Financials
Operating Income
$21.6B
↑ 31.6%
Net Income
$26.8B
↑ 90.6%
Gross Profit
$63.9B
↑ 4.2%
Revenue
$94.2B
↑ 6.0%
EPS (Diluted)
$11.03
↑ 90.5%
Total Liabilities
$117.7B
↑ 8.3%
Shareholders' Equity
$81.2B
N/A
Total Assets
$199.2B
↑ 10.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 13F-HR | 5/13/2026 | View on SEC |
| 4 | 5/4/2026 | View on SEC |
| SCHEDULE 13G | 5/1/2026 | View on SEC |
| 8-K | 4/28/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
| 4 | 4/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JNJ |
| Company Name | JOHNSON & JOHNSON |
| CIK | 200406 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0103 |
| State of Incorporation | NJ |
| Phone | 732-524-2455 |